Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> MutationRichard M. Stone, Hartmut Döhner, Frederick R. Appelbaum et al.|New England Journal of Medicine|2017Cited by 2.2k
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720Maria R. Baer, Richard A. Larson, Stephen L. George et al.|Journal of Clinical Oncology|2008Cited by 131
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)William Blum, Richard A. Larson, Ben L. Sanford et al.|Leukemia|2016Cited by 83
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001Geoffrey L. Uy, Richard A. Larson, Sumithra J. Mandrekar et al.|Blood Advances|2017Cited by 66
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)Heidi D. Klepin, Geoffrey L. Uy, Ellen K. Ritchie et al.|Journal of Geriatric Oncology|2019Cited by 55